CMP4_21_logo_full+color.jpg
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
March 21, 2024 07:58 ET | CAMP4 Therapeutics
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle D
Immuneering-logo (1).png
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
March 14, 2024 07:00 ET | Immuneering Corporation
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for...
Dyadic Logo Current.jpg
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Harpoon_logo (002).jpg
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
November 02, 2023 09:15 ET | Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
EW_logo_vertical.png
Earlyworks Co., Ltd. Launches Phase 1 of SDK Package for Grid Ledger System
October 31, 2023 16:05 ET | Earlyworks Co., Ltd.
Tokyo, Japan, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Earlyworks Co., Ltd. (Nasdaq: ELWS) (the “Company” or “Earlyworks”), a Japanese company operating its proprietary private blockchain technology, Grid...
invios-Logo-RGB-small.jpg
invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
September 05, 2023 03:00 ET | invIOs GmbH
Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started;invIOs awarded up to...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, FIRM Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RAIN
August 19, 2023 17:52 ET | The Rosen Law Firm PA
NEW YORK, Aug. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RAIN
July 27, 2023 11:27 ET | The Rosen Law Firm PA
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rain...
Algernon Logo 1.png
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
June 05, 2023 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Dyadic Logo Current.jpg
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
March 07, 2023 08:30 ET | Dyadic International, Inc.
Dosing of all patients was completed at the end of February  No Serious Adverse Events (SAE’s) have been reported  Phase 1 clinical initial safety and antibody response update expected in Q2, 2023  ...